These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25223691)

  • 1. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
    Yagi Y; Nakamura Y; Kitahara K; Harada T; Kato K; Ninomiya T; Cao X; Ohara H; Izumi-Nakaseko H; Suzuki K; Ando K; Sugiyama A
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):39-47. PubMed ID: 25223691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod (Gilenya
    Pilote S; Simard C; Drolet B
    Fundam Clin Pharmacol; 2017 Aug; 31(4):392-402. PubMed ID: 28299825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
    Pelz A; Schaffert H; Diallo R; Hiepe F; Meisel A; Kohler S
    Eur J Immunol; 2018 Mar; 48(3):498-508. PubMed ID: 29205338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
    Harada T; Wilbraham D; de La Borderie G; Inoue S; Bush J; Camm AJ
    Br J Clin Pharmacol; 2017 May; 83(5):1011-1027. PubMed ID: 27921320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue.
    Egom EE; Kruzliak P; Rotrekl V; Lei M
    J Cell Mol Med; 2015 Jul; 19(7):1729-34. PubMed ID: 25864579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The variant hERG/R148W associated with LQTS is a mutation that reduces current density on co-expression with the WT.
    Mechakra A; Vincent Y; Chevalier P; Millat G; Ficker E; Jastrzebski M; Poulin H; Pouliot V; Chahine M; Christé G
    Gene; 2014 Feb; 536(2):348-56. PubMed ID: 24334129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
    Feige J; Schernthaner C; Wipfler P; Sellner J
    Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
    Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
    Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
    Litwin T; Smoliński Ł; Członkowka A
    Neurol Neurochir Pol; 2018; 52(1):98-101. PubMed ID: 29110882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
    Camm J; Hla T; Bakshi R; Brinkmann V
    Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence from In Vivo Canine Models.
    Watanabe Y; Nakamura Y; Cao X; Ohara H; Yamazaki Y; Murayama N; Sugiyama Y; Izumi-Nakaseko H; Ando K; Yamazaki H; Sugiyama A
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):468-75. PubMed ID: 25370785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
    Hansen RS; Olesen SP; Rønn LC; Grunnet M
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):35-41. PubMed ID: 18594476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amitriptyline May Have Possibility to Induce Brugada Syndrome Rather than Long QT Syndrome.
    Lubna NJ; Wada T; Nakamura Y; Chiba K; Cao X; Izumi-Nakaseko H; Ando K; Naito AT; Satoh Y; Sugiyama A
    Cardiovasc Toxicol; 2018 Feb; 18(1):91-98. PubMed ID: 28616803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.
    Snelder N; Ploeger BA; Luttringer O; Rigel DF; Webb RL; Feldman D; Fu F; Beil M; Jin L; Stanski DR; Danhof M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):356-367. PubMed ID: 27934627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
    Orrico M; Nozzolillo A; Gelibter S; Sangalli F; Preziosa P; Filippi M; Moiola L
    J Neurol; 2021 Nov; 268(11):3975-3979. PubMed ID: 33852086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.